[Cell Reports] Using T cell and Treg cell-specific cGAS knockout mice, researchers demonstrated that nuclear cGAS promotes Treg cell development and function independently of its downstream adaptor STING.

[Cancer Discovery] Researchers show that activation of T cell-intrinsic p53 via carboxyl-terminal domain acetylation during immunotherapy activates the IFN-γ pathway, promotes CD8⁺ T cell infiltration, and elicits CD8⁺ T cell-dependent antitumor immunity.

[Lancet] Oncolytic viruses offer a promising approach, with the unique ability to selectively replicate within (and to destroy) cancer cells, remodel the immunosuppressive tumor microenvironment, and stimulate antitumor immunity.

[Clinical Cancer Research] Researchers examined a retrospective cohort of 125 patients with breast cancer, using targeted sequencing to identify clonal hematopoiesis of indeterminate potential (CHIP). In parallel, they developed chimeric mouse models of the two most mutated CHIP genes, DNMT3A and TET2.

[British Journal of Pharmacology] Scientists explored the effect of a hypoxia-inducible factor inhibitor on viability defect in human 3D breast cancer spheroids and the levels of prokineticin-2 in the conditioned medium following doxorubicin treatment.

[NRG Oncology] The NRG Oncology NRG-GU009 study evaluating intensified and de-intensified concurrent radiation regimens based on the genomic risk of patients with high-risk prostate cancer completed accrual and met its accrual milestone of 2,478 patients approximately two years earlier than the trial’s anticipated accrual completion date.

[Cell Death & Differentiation] Scientists demonstrated that ULK1 expression is positively correlated with both loss-of-function mutations in SPOP and the upregulation of the E3 ubiquitin ligase TRIM24 in human prostate cancer specimens.

[Cell Death & Differentiation] Scientists revealed that CCDC7_19-13 expression is markedly reduced in advanced and recurrent prostate cancer, where its low levels serve as an independent predictor of poor prognosis.

[Nature Medicine] This open-label phase I/II clinical study used a novel recombinant vector, rAAV-Olig001, with selective tropism for oligodendrocytes, to deliver gene therapy for Canavan disease.

[Nature Chemical Biology] Compared with adenosine deaminase acting on RNA (ADAR)-recruiting circular RNAs, researchers found that guided A>I snRNAs consistently increase adenosine-to-inosine editing for higher exon count genes, perturb substantially fewer off-target genes, and localize more persistently to the nucleus where ADAR is expressed.

[Molecular Therapy] The authors presented a strategy using lentiviral vector-mediated ex vivo hematopoietic stem/progenitor cell transplantation-gene therapy with a chimeric galactosylceramidase enzyme that incorporates peptides from alpha-L-iduronidase and apolipoprotein E II to enhance expression and blood-brain barrier penetration.

[Molecular Therapy] Investigators identified bone morphogenetic protein ligands (BMPs) as mediators of fibroadipose tissue deposition through in vitro experiments with human lymphedema fluid and BMP-specific inhibitor.